- About Us
- Media & News
- Contact HMRI
Researchers and clinicians in the HMRI Cancer Program are helping to reduce the incidence and risk of cancer by developing effective therapies and detection methods based on individual molecular profiles of this complex disease.
In 2012 the Hunter Cancer Research Alliance (HCRA) was established as an umbrella organisation of the four Cancer Research programs in the Hunter:
The Alliance also incorporates two national clinical trials groups based in the Hunter:
The Clinical Cancer Research Network facilitates efficient conduct of clinical trials, and optimises collaboration between 13 cancer clinical trials units throughout Hunter New England Health to increase participation, and ensure equity of opportunity exists to participate in research trials for all patients in rural, regional, metropolitan and private practices.
The Hunter Translational Cancer Research Unit provides enhanced infrastructure for bi-directional improvements in basic science and clinical care.
This includes the facilitation of research discoveries into health service implementation, and the stimulation of relevant laboratory research based on priority questions generated from the cancer clinics.
A key example of this bi-directional strategy is the HCRA’s commitment to enabling relevant breast cancer research by making breast cancer tissue available for biomedical study via the Hunter Biobank. This ongoing collection of tissue has led to the establishment of a number of formal international collaborations with key cancer research institutions, including Cancer Research UK and the International Breast Cancer Intervention Group.
In addition, researchers have facilitated the delivery of faster and more extensive breast cancer risk testing to patients within the Hunter region, as Next Generation (Next-Gen) DNA sequencing technologies which enable such improvements are now in use by the Hunter Area Pathology Service (A Division of Pathology North). This is the first laboratory in Australia to gain approval for the use of Next-Gen sequencing in diagnostic services.
The vision of the HTCRA is to establish the Hunter and New England regions as a competitive global hub of excellence in collaborative translational cancer research. The Alliance provides capacity building, funding and strategic support to cancer research across the full research practice continuum.
Many of the Hunter’s cancer researchers are affiliated with the University of Newcastle’s Priority Research Centre for Cancer; the Priority Research Centre for Bioinformatics, Biomarker Discovery & Information-Based Medicine; and the Priority Research Centre for Health Behaviour.
Program Leader: Professor Stephen Ackland, Calvary Mater Newcastle.
For more information about the HMRI Cancer Program, you can also visit the Hunter Cancer Research Alliance website.